ArticleFrontiers in oncology2025
Promising outcomes of the PD-L1 inhibitor Socazolimab in recurrent and metastatic cervical cancer: a case report.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent and metastatic advanced cervical cancer carries a poor prognosis, and there is currently no standardized treatment regimen. Immunotherapy, as an emerging and effective treatment strategy, has attracted significant attention. Socazolimab, a programmed death ligand 1 monoclonal antibody developed in China, is primarily used to treat patients with recurrent or metastatic cervical cancer who have failed or are intolerant to first-line platinum-based chemotherapy, regardless of programmed death ligand 1 expression status. We report the case of a Chinese patient with advanced cervical cancer and multiple metastases, who showed significant tumor regression after receiving Socazolimab treatment. Currently, during ongoing immunotherapy, the tumor continues to demonstrate persistent remission, with no new lesions observed. This case suggests that Socazolimab may offer a promising therapeutic option for patients with metastatic cervical cancer. In this report, the safety profile of Socazolimab was favorable, with no severe or uncontrollable adverse events. This case provides compelling evidence of the antitumor activity and manageable toxicity of Socazolimab in metastatic cervical cancer patients, offering valuable insights for further research and clinical application of the drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.